Improved OutcomesSystems Influence The BRAVE HEART Study Aims to Transform Early Detection and Management of Pre-Heart Failure
A major international study is underway to improve the early identification and management of patients with pre-heart failure and cardiometabolic-renal multi-morbidity, using routinely collected health data from the UK, Denmark, and the US.
This large-scale, decentralised observational study is designed to reflect real-world clinical practice and identify unmet needs and treatment gaps. It also aims to establish a robust platform for conducting pragmatic clinical trials using routine data—paving the way for the development of new technologies to manage multiple long-term conditions (MLTC).
The study protocol and statistical analysis plan (SAP) have been finalised. The first virtual Steering Committee (SC) meeting took place in December 2024, followed by an in-person meeting in London on 23 January 2025. Ethical and regulatory approvals are expected in the first half of 2025, with data collection set to begin in the second half of the year.
Innovative Approach to Data Collection
The study introduces a novel approach to recruitment and data collection. Patient data will be gathered through routine medical systems via data linkage, uploaded into an electronic data capture (EDC) system, and supplemented through an interactive patient portal (via web or app). This design ensures efficiency and scalability while maintaining patient engagement.
The project is a collaboration between leading academic institutions, including the University of Copenhagen and Boston University/VA System, and is supported by the NIHR Imperial BRC Digital Health Theme.
Policy and Research Impact
In the long term, the study is expected to influence health policy by:
- Documenting current clinical practices
- Highlighting treatment gaps
- Supporting the development of precision medicine approaches
- Enabling digital tools to emulate clinical trials and predict treatment outcomes using electronic health records
By aligning with national priorities in precision medicine and digital health innovation, this study represents a significant step forward in tackling the growing burden of MLTC and improving patient outcomes.
